LUTATHERA

Indicated For

somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

About This Medication

# Novartis Patient Support Patient Guide: How to Get LUTATHERA at Low or No Cost LUTATHERA® (lutetium Lu 177 dotatate) is a prescription medicine used to treat adults and children aged 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), a type of cancer affecting the digestive system.[5] Novartis Patient Support offers financial help through programs like Co-Pay Plus, which can reduce your out-of-pocket costs to as little as $0 for eligible commercially insured patients, with up to $15,000 annual assistance.[1][9] This guide explains eligibility, application steps, and more to help you access LUTATHERA affordably. ## About LUTATHERA and Why Assistance Matters LUTATHERA is a targeted radioligand therapy that delivers radiation directly to GEP-NET cancer cells expressing somatostatin receptors, helping to control tumor growth.[5] Treatment typically involves intravenous infusions every 8 weeks for up to 4 doses, administered in a specialized facility.[1] Without assistance, costs can be high—85% of insured patients paid $0 for the product after support, but others face significant out-of-pocket expenses.[2] Novartis Patient Support navigates insurance, verifies benefits, and provides copay help to make treatment accessible.[1][2] ## Who Qualifies for Novartis Patient Support? **Co-Pay Programs (e.g., Co-Pay Plus, Plus Card, Rebate):** Primarily for patients with **commercial (private) insurance** covering LUTATHERA. Government insurance like Medicare, Medicaid, TRICARE, VA, or DoD does not qualify—you'll pay full costs once limits are reached.[1][7][9] Patients must use their insurance (not cash pay), and the plan must not fully reimburse the drug.[9] No specific income limits are listed for copay help; it's focused on reducing copays, coinsurance, and deductibles up to $15,000 per year.[1][9] **Novartis Patient Assistance Foundation (NPAF):** For uninsured, underinsured, or those unable to afford meds. Requires U.S. residency, outpatient treatment by a U.S. provider, and meeting **income guidelines** (less than ~400-500% FPL based on household size) plus out-of-pocket requirements. Medicare patients have separate criteria.[2][3][4] Contact NPAF at 1-800-277-2254 or visit www.PAP.Novartis.com for details.[2] ## Income Eligibility Breakdown Copay programs have no published income thresholds, but NPAF does. Exact limits vary by product, household size, and out-of-pocket spend—submit your tax return's first two pages for verification.[4] Here's a sample from NPAF's Lutathera grid (as of 2024; call to confirm current): | Household Size | Max Annual Income (Low Tier) | Max Annual Income (High Tier) | Add per Extra Member | Out-of-Pocket Req. | |---------------|------------------------------|-------------------------------|----------------------|--------------------| | 1 | ~$60,000 | ~$75,000 | $15,000 | Varies[4] | | 2 | ~$80,000 | ~$100,000 | $20,000 | Varies[4] | | 3 | $100,000 | $125,000 | $25,000 | Varies[4] | | 4 | $120,000 | $150,000 | $30,000 | Varies[4] | *Notes: Figures approximated from PDF grid (e.g., 4-person: $187,200/$234,000).[4] All except Medicare/uninsured meet specific OOP; details not fully public—**contact program**.[2][4] Income based on prior year's tax return. ## Insurance Requirements - **Commercial/Private Insurance:** Eligible for copay assistance if LUTATHERA is covered (76% of plans do as of Jan 2025).[2] Support includes prior auth help, benefits verification, and appeals.[1][2] - **Government Insurance (Medicare/Medicaid):** **Not eligible** for copay programs.[7][9] NPAF may help Medicare patients if income/OOP criteria met.[2][4] - **Uninsured:** Apply to NPAF for free medication if eligible.[2][3] Novartis verifies coverage first—76% covered, 24% pending plan decision.[2] ## Step-by-Step Application Process 1. **Discuss with Your Doctor:** Confirm LUTATHERA is right; get prescription. Doctor completes **START Form** (includes insurance details, attestation of medical necessity). Fax to 1-844-638-7329 or use HCP portal.[7] 2. **Call Novartis Patient Support:** Dial **(844) 638-7222** (Mon-Fri 8AM-8PM ET).[1][5] Enroll, request benefits verification—they check coverage, prior auth needs.[2] 3. **Submit Documents:** Provide **proof of income** (tax return pages 1-2), **insurance info**, **prescription**, **physician verification**.[3][4][7] Multiple methods: phone, fax, online portal.[1] 4. **Choose Program:** Commercially insured? Opt for Co-Pay Plus (fill claim form, mail/fax).[9] Uninsured/low-income? NPAF application via doctor and you.[3] 5. **Sign Agreements:** Agree to terms (e.g., no government insurance for copay).[7][9] Your support team handles navigation.[1] ## Timeline and Delivery - **Processing:** Varies; NPAF decisions in ~4 weeks.[3] Copay claims quick post-verification.[9] START Form incompleteness delays treatment.[7] - **Delivery:** Shipped to **physician's office** or treatment center; real-time tracking available.[10] Infused outpatient.[2] - **Reauthorization:** **Required** for refills/continued treatment—resubmit verification.[provided] ## Alternatives if Denied or Ineligible - **Appeal Insurance Denial:** Novartis helps with prior auth/appeals.[2] - **NPAF if Copay No-Go:** Switch if uninsured/underinsured.[2] - **Other Funds:** Assistance Fund (Pancreatic Cancer, waitlist) or general copay cards.[8] - **Treatment Centers:** Locator via support line.[10] - **No Biosimilars** available.[provided] ## Important Disclaimer This guide is for informational purposes based on available sources as of 2026—programs change. **Always contact Novartis Patient Support at (844) 638-7222 or NPAF at 1-800-277-2254** for personalized eligibility, current limits, and applications. Not medical/financial advice; consult your doctor/insurer. Assistance not guaranteed; terms apply (e.g., $15K cap, calendar year reset).[1][9] LUTATHERA has risks—discuss with provider.[5] (Word count: 1028)

Program information last verified: March 30, 2026